RBC Downgrades Regeneron Pharmaceuticals (REGN) to Sector Perform
REGN Hot Sheet
Rating Summary:9 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 7 | New: 18
RBC downgrades Regeneron Pharmaceuticals (Nasdaq: REGN) from Outperform to Sector Perform.
To see more analyst ratings on REGN Click Here.
Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States.
To see more analyst ratings on REGN Click Here.
Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
